These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34482535)

  • 1. Mild COVID-19 and Impaired Blood Cell-Endothelial Crosstalk: Considering Long-Term Use of Antithrombotics?
    Melkumyants A; Buryachkovskaya L; Lomakin N; Antonova O; Serebruany V
    Thromb Haemost; 2022 Jan; 122(1):123-130. PubMed ID: 34482535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enoxaparin dose impacts blood cell phenotypes during mild SARS-CoV-2 infection: the observational single-center study.
    Buryachkovskaya L; Lomakin N; Melkumyants A; Docenko J; Ermishkin V; Serebruany V
    Rev Cardiovasc Med; 2021 Dec; 22(4):1685-1691. PubMed ID: 34957811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating endothelial progenitors are increased in COVID-19 patients and correlate with SARS-CoV-2 RNA in severe cases.
    Mancuso P; Gidaro A; Gregato G; Raveane A; Cremonesi P; Quarna J; Caccia S; Gusso L; Rusconi S; Giacomelli A; Cogliati C; Bertolini F
    J Thromb Haemost; 2020 Oct; 18(10):2744-2750. PubMed ID: 32762140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral Coagulopathy in Patients With COVID-19: Treatment and Care.
    Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J
    Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated Cytokine Levels in Plasma of Patients with SARS-CoV-2 Do Not Contribute to Pulmonary Microvascular Endothelial Permeability.
    Kovacs-Kasa A; Zaied AA; Leanhart S; Koseoglu M; Sridhar S; Lucas R; Fulton DJ; Vazquez JA; Annex BH
    Microbiol Spectr; 2022 Feb; 10(1):e0167121. PubMed ID: 35171047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 infection and thrombotic complications: a narrative review.
    Moschonas IC; Tselepis AD
    J Thromb Thrombolysis; 2021 Jul; 52(1):111-123. PubMed ID: 33449290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy.
    Chang JC
    Vasc Health Risk Manag; 2021; 17():273-298. PubMed ID: 34103921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. State-of-the-art review - A review on snake venom-derived antithrombotics: Potential therapeutics for COVID-19-associated thrombosis?
    Kalita B; Saviola AJ; Samuel SP; Mukherjee AK
    Int J Biol Macromol; 2021 Dec; 192():1040-1057. PubMed ID: 34656540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases.
    Colmenero I; Santonja C; Alonso-Riaño M; Noguera-Morel L; Hernández-Martín A; Andina D; Wiesner T; Rodríguez-Peralto JL; Requena L; Torrelo A
    Br J Dermatol; 2020 Oct; 183(4):729-737. PubMed ID: 32562567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study.
    Russo V; Di Maio M; Attena E; Silverio A; Scudiero F; Celentani D; Lodigiani C; Di Micco P
    Pharmacol Res; 2020 Sep; 159():104965. PubMed ID: 32474087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombotic complications of COVID-19 may reflect an upregulation of endothelial tissue factor expression that is contingent on activation of endosomal NADPH oxidase.
    DiNicolantonio JJ; McCarty M
    Open Heart; 2020 Jun; 7(1):. PubMed ID: 32532805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale for the Role of Heparin and Related GAG Antithrombotics in COVID-19 Infection.
    Magnani HN
    Clin Appl Thromb Hemost; 2021; 27():1076029620977702. PubMed ID: 33539214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research.
    Bikdeli B; Madhavan MV; Gupta A; Jimenez D; Burton JR; Der Nigoghossian C; Chuich T; Nouri SN; Dreyfus I; Driggin E; Sethi S; Sehgal K; Chatterjee S; Ageno W; Madjid M; Guo Y; Tang LV; Hu Y; Bertoletti L; Giri J; Cushman M; Quéré I; Dimakakos EP; Gibson CM; Lippi G; Favaloro EJ; Fareed J; Tafur AJ; Francese DP; Batra J; Falanga A; Clerkin KJ; Uriel N; Kirtane A; McLintock C; Hunt BJ; Spyropoulos AC; Barnes GD; Eikelboom JW; Weinberg I; Schulman S; Carrier M; Piazza G; Beckman JA; Leon MB; Stone GW; Rosenkranz S; Goldhaber SZ; Parikh SA; Monreal M; Krumholz HM; Konstantinides SV; Weitz JI; Lip GYH;
    Thromb Haemost; 2020 Jul; 120(7):1004-1024. PubMed ID: 32473596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin.
    Qian Y; Lei T; Patel PS; Lee CH; Monaghan-Nichols P; Xin HB; Qiu J; Fu M
    J Virol; 2021 Nov; 95(23):e0139621. PubMed ID: 34549987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence.
    Godino C; Scotti A; Maugeri N; Mancini N; Fominskiy E; Margonato A; Landoni G
    Int J Cardiol; 2021 Feb; 324():261-266. PubMed ID: 33002521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.